基于脂质体的原蛋白输送系统的开发和表征,具有持续释放和保存抗氧化活性
Helin Wan1, Yiming Jiang1, Shaojun Yun1
1College of Food Science and Engineering, Shanxi Agricultural University, Taigu, Shanxi 030801, China.
Food chemistry
|March 11, 2026
概括
这项研究开发了一种基于脂质体的原蛋白输送系统 (Lip-COL),以提高原蛋白的稳定性和功能. Lip-COL有效地保护原蛋白免受降解,确保其传递并保持抗氧化活性.
科学领域:
- 食品科学与技术 食品科学与技术
- 纳米技术纳米技术
- 营养保健品 营养保健品
背景情况:
- 原蛋白具有宝贵的营养和功能性质.
- 它在食品中的应用受到不稳定性和消化系统崩的限制.
- 需要新的输送系统来增强原蛋白的稳定性和生物可用性.
研究的目的:
- 开发和描述一种基于脂质体的原蛋白输送系统 (Lip-COL).
- 为了评估Lip-COL的物理化学特性.
- 评估封装原蛋白的稳定性,释放动力学和生物功能性.
主要方法:
- 脂质体的配方和表征 (粒子大小,泽塔潜力,形态).
- 确定原封装效率的方法.
- 稳定性测试 (热,pH,离子强度).
- 在体外释放研究和模拟消化试验.
- 抗氧化剂活性评估.
主要成果:
- Lip-COL 呈现球形形态,粒子大小为 ~215 nm,负泽塔电位 (-18.87 mV).
- 封装效率很高 (~70%),而Lip-COL显示了伪塑性流.
- 封装显著改善了对抗各种压力因素的原体稳定性.
- 观察到持续释放,延迟t50 (1.1小时) 和t80 (7.7小时),减少了26%的爆发释放.
- 原蛋白的抗氧化活性在封装后和模拟消化后被保留.
结论:
- 脂质体封装是一种有效的策略,可以增强原的稳定性和生物功能性.
- Lip-COL确保了肠道输送,并保留了原蛋白的抗氧化特性.
- 这种纳米输送系统有可能将原蛋白作为食补充剂和功能性食品成分.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
01:19Modified-Release Drug Delivery Systems: Overview
235
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
235
01:20Modified-Release Drug Delivery Systems: Influencing Factors
208
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
208
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
257
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
257
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164